Evidence map›Paper›PMID 30406605›Full record

ArticleJournal of nephrology2019

Infusion of autologous bone marrow derived mononuclear stem cells potentially reduces urinary markers in diabetic nephropathy.

Abduzhappar Gaipov, Zhannat Taubaldiyeva, Manarbek Askarov, Zaiyrkhan Turebekov, Larisa Kozina, Askhat Myngbay, Olga Ulyanova, Saltanat Tuganbekova

Abstract readClinical Study
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Abduzhappar GaipovDepartment of Extracorporeal Hemocorrection, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009. abduzhappar@gmail.com.ORCID http://orcid.org/0000-0002-9844-8772
Zhannat TaubaldiyevaDepartment of Endocrinology, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009.
Manarbek AskarovDepartment of Stem Cell Technology, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009.
Zaiyrkhan TurebekovDepartment of Internal Medicine, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009.
Larisa KozinaDepartment of Biochemistry, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009.
Askhat MyngbayPrivate Institution "National Laboratory Astana", Nazarbayev University, Astana, Kazakhstan.
Olga UlyanovaDepartment of Endocrinology, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009.
Saltanat TuganbekovaDepartment of Internal Medicine, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009.
National Medical Holding · KZNazarbayev University · KZ

Funding

Ministry of Healthcare of Republic of Kazakhstan N 0104 RK 00133
6 · The paper itself

Abstract

backgroundDiabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide. Previous studies demonstrated safety and efficacy of autologous bone marrow-derived mononuclear cells (ABM-MNCs) in induced type-1 diabetes mellitus (T1DM) rats. However, the effect of ABM-MNCs on urinary markers of DN in humans is not well studied. We evaluated the therapeutic effect of ABM-MNCs on the urinary markers microalbuminuria (MAU), urinary type-IV collagen and urinary neutrophil gelatinase-associated lipocalin (uNGAL) in T1DM patients with and without nephropathy.

methodsThis prospective open-label pilot study included 15 patients with T1DM, who had completed 2 visits within 6 months. Patients were divided into two groups according to the presence (DN, n = 7) and absence of nephropathy (T1DM, n = 8). ABM-MNCs were injected at each visit as per study protocol. Routine laboratory data, diabetes tests (fasting serum C-peptide and insulin, glycated hemoglobin, fasting and postprandial glucose), 24-h MAU and urinary type-IV collagen were measured at each visit. uNGAL levels were studied before and after 3 days of ABM-MNCs infusion at each visit.

resultsMean age of patients was 29.2 ± 10.4 years, 33% were male, and 27% of the overall group had hypertension. MAU was significantly reduced in the overall group (- 26.0%, p = 0.037), including in DN (- 83.2%, p = 0.021). A short-term significant reduction of uNGAL levels was observed 3 days after ABM-MNCs administration during the both the 1st visit (median 13.4 vs. 9.5 ng/ml, p = 0.027) and 2nd visit (median 8.8 vs. 6.4 ng/ml, p = 0.042) in both groups. However this reduction did not remain significant at the 6-month follow-up. Urinary type-IV collagen did not respond significantly to ABM-MNCs infusion.

conclusionInfusion of autologous bone marrow-derived mononuclear cells significantly reduced levels of MAU in DN patients. Further studies with larger sample size are needed to confirm these observations.

Indexed as

Bone Marrow TransplantationAdultAlbuminuriaBiomarkersCells, CulturedCollagen Type IVDiabetes Mellitus, Type 1Diabetic NephropathiesDown-RegulationFemaleHumansLipocalin-2MaleMiddle AgedPilot ProjectsProspective StudiesBiomarkersCollagen Type IVLCN2 protein, humanLipocalin-2Autologous bone-marrow derived stem cellsMicroalbuminuriaType-1 diabetes mellitus, nephropathyUrinary neutrophil gelatinase-associated lipocalin

Identifiers

PMID30406605
OpenAlexW2899830380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.